
Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion
Upregulation of the neuronal fragile X mental retardation protein in cancer cells suppresses proinflammatory signals to circumvent tumor immunity
Read MoreDual Inhibitor
of CSF1R and TRK
TEAD
Inhibitor
BET
Inhibitor
FMRP
Inhibitor
In addition to its discovery-stage FMRP program, Opna’s lead clinical compound, OPN-2853, a bromo and extra terminal (BET) domain inhibitor, is currently in a Phase 1/2 trial with ruxolitinib (Jakafi®) in myelofibrosis, a chronic bone marrow disorder. The company also expects to initiate a Phase 2 study with OPN-7486, a colony stimulating factor 1 (CSF1) receptor inhibitor, in patients with histiocytosis, a white blood cell disorder, in the first half of 2023.
EXPLOREUpregulation of the neuronal fragile X mental retardation protein in cancer cells suppresses proinflammatory signals to circumvent tumor immunity
Read MoreGideon Bollag, PhD, Named CEO and Board Director.